NEW YORK (GenomeWeb) — Bio-Rad reported after the close of the market Tuesday an 11 percent decrease in third quarter revenues, including a 13 percent decrease in sales for its Life Science segment.

For the three months ended Sept. 30, Bio-Rad reported revenues of $470 million compared to $530.6 million in the year-ago period, and below analysts’ consensus estimate of $495.6 million. On a currency-neutral basis, Bio-Rad's Q3 revenues decreased 2.2 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.